Written with AI assistance from PeptideCompare’s published data.
These notes pull together what our data showed this month. Every figure comes from a page on the site, and each section links to it. Figures are as of November 14, 2026.
Prices: the typical listing costs five times the cheapest tested one
Across peptides sold by at least five independently tested vendors, the median listing costs 5.0 times as much per milligram as the cheapest. The widest gaps:
| Peptide | Cheapest per mg | Median per mg | Gap |
|---|---|---|---|
| SLU-PP-332 | USD 0.232 | USD 7.50 | 32.4× |
| AHK-Cu | USD 0.010 | USD 0.310 | 31.0× |
| GHK-Cu | USD 0.019 | USD 0.450 | 23.8× |
| Snap-8 | USD 0.105 | USD 2.50 | 23.8× |
| Lipo-C | USD 0.105 | USD 1.85 | 17.6× |
| Semaglutide | USD 0.238 | USD 3.00 | 12.6× |
| NAD+ | USD 0.006 | USD 0.075 | 12.5× |
A caution on reading this: large vials and multi-vial kits pull the cheapest figure down, so the gap partly reflects pack size. And a price per milligram compares cost, not effect.
Source: Peptide price statistics 2026: cost per mg and vendor data · PeptideCompare
Lab reports: one in four
For 24% of vendor and peptide combinations in our data, the vendor publishes a readable lab report for that peptide. Coverage is far from even. More than half of the vendors selling retatrutide (56%) and tirzepatide (53%) publish one. For VIP, oxytocin and FOXO4-DRI it is under 10%.
Publishing a report is not the same as the report being checkable. Of 5,120 published reports from independent labs, 39% link to a copy on the lab’s own site. Ten vendors are banned from the site for fake or doctored reports.
Source: How to verify a peptide COA: lab-by-lab verification guide · PeptideCompare
Research: nearly half the library has no controlled human trial
Of 112 graded compounds, 19 are an A (strong human evidence), 39 a B, 33 a C (mostly animal studies) and 21 a D (little or no evidence for the exact molecule). That leaves 54 with no controlled human trial of the molecule itself.
Source: Peptide research: what the studies show for 112 peptides · PeptideCompare
Regulation: six recommended, none legal yet
FDA’s Pharmacy Compounding Advisory Committee voted in July to recommend BPC-157, Epithalon, KPV, MOTS-c, Semax and TB-500 for the 503A bulks list, against FDA staff’s advice, and voted against DSIP. The votes are not binding. No proposed rule had been published when we last checked, on October 8. A further review, covering GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF, is planned by February 2027.
Source: Which peptides can be compounded in the US? FDA 503A status · PeptideCompare
Trials: 718 recruiting
We track 4,632 registered trials of 55 peptides from ClinicalTrials.gov. 718 are recruiting, 1,048 are in phase 3 and 976 have posted results. 402 were stopped or withdrawn.
Source: Peptide clinical trials: 718 recruiting now, 4632 registered · PeptideCompare
Using these numbers
They are free to quote with a link. Suggested credit: PeptideCompare, “Peptide price statistics”, peptidecompare.net/statistics/, figures as of 2026-11-14.
PeptideCompare earns affiliate commission from some vendor links. Rankings use price per milligram and lab evidence only, and nobody can pay to be listed or ranked higher. Nothing here is medical advice.
The Community Rules apply here: research discussion only, no dosing or personal-use advice, no buying, selling or sourcing requests, and disclose any vendor connection.